Just going thru the report in much more detail.
Either $0 copay or minimal for claims not covered should promote people suffering from PAH to get it if no out of pocket, or what I would imagine is similar to OTC anti perspirant or not too much more.
So if the end user gets covered and $0 copay why would they at least not try it?
The potential revenue from a product averaging $500 to $600 per unit is immense.
I also read the report prescribes 0 to the other pipelines
So plenty of upside
BOT train waiting for 1 more green light before it's full power ahead
BOT - Post Approval Takeover Predictions, page-50
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.050(14.3%) |
Mkt cap ! $724.0M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 40.0¢ | 35.5¢ | $6.075M | 15.87M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 287187 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 1920397 | 33 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |